Ascletis Pharma Inc.

Investors

2025

2024

2023

2022

2021

2020

2019

2018

Voluntary Announcement - Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
2025-12-15
Next Day Disclosure Returns - Share Buyback
2025-12-12
Voluntary Announcement - Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
2025-12-10
Voluntary Announcement - Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
2025-12-08
Next Day Disclosure Returns - Share Buyback
2025-12-04
Next Day Disclosure Returns - Share Buyback
2025-12-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
2025-12-02
Voluntary Announcement - Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
2025-11-30
Voluntary Announcement - Ascletis Announces Co-Formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
2025-11-13
Next Day Disclosure Returns - Share Buyback
2025-11-05

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1